Literature DB >> 19171434

MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer.

Ming Shi1, Ning Guo.   

Abstract

Alterations in microRNA (miRNA) expression have been associated with tumor suppression or tumorigenesis, metastasis and poor prognosis in human breast cancer. Deregulation of miRNAs is emerging as a major aspect of cancer etiology because their capacity to direct the translation and stability of targeted transcripts can dramatically influence cellular physiology. Some miRNAs were considered to be associated with molecular subtypes of breast cancer and correlated with specific breast cancer clinicopathological factors, such as HER2, estrogen and progesterone receptor level, tumor stage, vascular invasion, or proliferation index. The expression level of miRNAs as suppressors, which can inhibit the expression of tumor promoting genes, is frequently down-regulated in breast cancer. Multiple lines of evidence also demonstrated the involvement of specific miRNAs as oncogenes in breast tumorigenesis. Some miRNAs have been considered to have potential clinical applications as a novel biomarker for breast cancer diagnosis and prognostic factor. Exploitation of the therapeutic potential of RNA interference will be an important task and achieved through the further understanding of the mechanisms of gene regulation by miRNAs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19171434     DOI: 10.1016/j.ctrv.2008.12.002

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  38 in total

Review 1.  microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles.

Authors:  Kirti Bhatt; Qing-Sheng Mi; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-12

Review 2.  MicroRNAs in gastric cancer: from benchtop to bedside.

Authors:  Fuyi Tong; Peng Cao; Yuan Yin; Suhua Xia; Rensheng Lai; Shenlin Liu
Journal:  Dig Dis Sci       Date:  2013-10-10       Impact factor: 3.199

3.  Ischemia caused by time to freezing induces systematic microRNA and mRNA responses in cancer tissue.

Authors:  Eldrid Borgan; Roy Navon; Hans Kristian Moen Vollan; Ellen Schlichting; Torill Sauer; Zohar Yakhini; Ole Christian Lingjærde; Therese Sørlie; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2011-08-29       Impact factor: 6.603

4.  miR-29b regulates migration of human breast cancer cells.

Authors:  Chen Wang; Zhen Bian; Da Wei; Jian-guo Zhang
Journal:  Mol Cell Biochem       Date:  2011-02-26       Impact factor: 3.396

5.  Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer.

Authors:  Shadan Ali; Khaldoun Almhanna; Wei Chen; Philip A Philip; Fazlul H Sarkar
Journal:  Am J Transl Res       Date:  2010-09-28       Impact factor: 4.060

6.  Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells.

Authors:  Aamir Ahmad; Amro Aboukameel; Dejuan Kong; Zhiwei Wang; Seema Sethi; Wei Chen; Fazlul H Sarkar; Avraham Raz
Journal:  Cancer Res       Date:  2011-03-09       Impact factor: 12.701

Review 7.  Biomarkers for colorectal cancer.

Authors:  Takuji Tanaka; Mayu Tanaka; Takahiro Tanaka; Rikako Ishigamori
Journal:  Int J Mol Sci       Date:  2010-09-13       Impact factor: 5.923

8.  miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w.

Authors:  Lei Shen; Jia Li; Liping Xu; Jie Ma; Hua Li; Xigang Xiao; Junyong Zhao; Lin Fang
Journal:  Exp Ther Med       Date:  2011-12-22       Impact factor: 2.447

9.  MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer.

Authors:  Chuankui Wei; Qifeng Luo; Xiaoguo Sun; Dengfeng Li; Hongming Song; Xiaoyu Li; Jialu Song; Kaiyao Hua; Lin Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 10.  Current molecular diagnostics of breast cancer and the potential incorporation of microRNA.

Authors:  Christine K Zoon; Elizabeth Q Starker; Arianne M Wilson; Michael R Emmert-Buck; Steven K Libutti; Michael A Tangrea
Journal:  Expert Rev Mol Diagn       Date:  2009-07       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.